GSK ‘plays its part’ in tackling Aids crisis

GlaxoSmithKline (GSK) has reported that the firm is continuing to play a role in dealing with the global Aids crisis, with the company giving its consent for a Canadian firm Apotex to manufacture a generic treatment for HIV/Aids in Rwanda.

The company reports that – under the Access to Medicines Regime in Canada – it has granted permission for the production of a generic fixed-dose combination antiretroviral containing lamivudine and zidovudine, two molecules over which GSK has patent rights.

GSK notes that it will waive all royalties on this product, as the triple-combination antiretroviral supplied by Apotex will be sold on a non-profit basis.

Reflecting the World Trade Organisation 31f agreement of August 2003, the Access to Medicines Regime facilitates the authorisation of production of patented treatments for the export market.

Paul Lucas, president and chief executive of GSK Canada, said: “Tackling the AIDS crisis is one of the greatest challenges the world faces.

“GSK continues to play its part to tackle this crisis through research and development, not-for-profit pricing and ongoing investment in dedicated community programmes.”

He added that the decision to permit Apotex to manufacture a treatment containing its molecules is part of this dedication.

Last month, GSK presented clinical trial results showing the similar efficacy and lipid effects of HIV treatments Lexiva (fosamprenavir calcium) and atazanavir.